|
Age (years)
|
74.9 ± 8.4
|
|
Male gender
|
1647 (61.9%)
|
|
Obesity
|
766 (31.6%)
|
|
Admission blood glucose (mg/dL)
|
153 ± 45.7
|
|
Admission serum creatinine (mg/dL)
|
1.03 ± 0.23
|
|
Admission aspartate aminotransferase (U/L)
|
31 ± 8
|
|
Admission alanine aminotransferase (U/L)
|
26 ± 6
|
|
Metformin
|
1618 (60.8%)
|
|
DPP-4i
|
791 (30.2%)
|
|
GLP1-1RA
|
127 (4.8%)
|
|
SGLT-2i
|
296 (11.3%)
|
|
Insulin
|
723 (27.6%)
|
|
Angiotensin-converting enzyme inhibitor
|
724 (27.4%)
|
|
Angiotensin II receptor blocker
|
789 (29.9%)
|
|
Statin
|
1534 (58.0%)
|
|
Antiplatelet
|
643 (24.8%)
|
|
Anticoagulant
|
(16.3%)
|
|
History of smoking
|
955 (35.8%)
|
|
Hypertension
|
2026 (76.2%)
|
|
Dyslipidemia
|
1730 (65.0%)
|
|
Chronic kidney disease
|
352 (13.2%)
|
|
Atrial fibrillation
|
444 (16.7%)
|
|
Coronary artery disease
|
610 (22.9%)
|
|
Heart failure
|
445 (16.7%)
|
|
Chronic obstructive pulmonary disease
|
346 (13.0%)
|
|
Liver disease
|
172 (6.5%)
|
|
Cancer
|
353 (13.3%)
|
|
Stroke
|
322 (12.1%)
|
|
Dementia
|
384 (14.4%)
|
|
Depression
|
308 (11.6%)
|
|
Moderate-severe functional dependence
|
636 (24.2%)
|
|
Moderate-severe comorbidity
|
2338 (90.7%)
|
|
Disease severity
|
|
Moderate
|
1891 (70.9%)
|
|
Severe
|
714 (26.8%)
|
|
Critical
|
61 (2.3%)
|
|
Hydroxychloroquine
|
2185 (82.0%)
|
|
Chloroquine
|
72 (2.7%)
|
|
Lopinavir/ritonavir
|
1195 (44.8%)
|
|
Azithromycin
|
1595 (59.8%)
|
|
Remdesivir
|
36 (1.4%)
|
|
Interferon-β
|
276 (10.4%)
|
|
Corticosteroids
|
1186 (44.5%)
|
|
Tocilizumab
|
215 (8.1%)
|
